Measurement of immune markers in the serum and cerebrospinal fluid of multiple sclerosis patients during clinical remission
- 44 Downloads
Magnetic resonance imaging of multiple sclerosis (MS) patients often shows active inflammatory lesions despite clinical remission. No immunological marker of disease activity has been identified in these patients. Concentrations of neopterin, interleukin-2 (IL-2), soluble interleukin-2 receptor (sIL-2R) and tumour necrosis factor-α (TNF-α) were measured in the serum and cerebrospinal fluid of 19 clinically-inactive MS patients and compared with those of 19 non-inflammatory controls. Cerebrosipnal fluid (CSF) neopterin concentrations were significantly higher in the MS group than in controls (mean 9.1 mM vs 3.4 nM,P<0.01) and 10 of 19 MS patients had levels above the control range. This finding provides evidence of ongoing T-cell-directed and interferon-gamma-mediated macrophage activation in the central nervous system. Analysis of IL-2, sIL-2R and TNF-a concentrations revealed no significant differences between MS patients and controls. We conclude that CSF neopterin concentration may correlate with disease activity in asymptomatic patients.
Key wordsMultiple sclerosis Immune markers Neopterin
Unable to display preview. Download preview PDF.
- 4.Capra R, Mattioli F, Marciano N, Vignolo LA, Bettinzioli M, Airo P, Cattaneo R (1990) Significantly higher levels of soluble interleukin 2 in patients with relapsing-remitting multiple sclerosis compared with healthy subjects. Arch Neurol 47:254Google Scholar
- 5.Editorial (1989) Immunological treatment for multiple sclerosis. Lancet 1:699–671Google Scholar
- 16.Greenburg SJ, Marcon L, Hurwitz BJ, Waldmann TA, Nelson DL (1988) Elevated levels of soluble interleukin-2 receptors in multiple sclerosis. N Enlg J Med 319:1019Google Scholar
- 17.Group TIMSS (1993) Interferon betalb is effective in relapsing- remitting multiple sclerosis. I. Clinical results of a multicenter, randomized, doubleblind, placebo-controlled trial. Neurology 43:655–661Google Scholar
- 24.Maimone D, Gregory S, Arnason BGW, Reder AT (1991) Cytokine levels in the cerebrospinal fluid and serum of patients with multiple sclerosis. J Neuroimmunal 32:67–74Google Scholar
- 25.McIntosh J, Murray-McIntosh R (1991) MacRIA, Wellington School of Medicine, P O Box 7343, Wellington, New ZealandGoogle Scholar
- 29.Panitch H, Folus J, Johnson K (1987) Recombinant beta interferon inhibits gamma interferon production in multiple sclerosis (abstract). Ann Neurol 22:139Google Scholar
- 34.Rudick RA, Barna BP (1990) Serum interleukin 2 and soluble interleukin 2 receptor in patients. Arch Neurol 47:254–255Google Scholar
- 41.Traugott U, Lebon P (1989) Demonstration of alpha, beta and gamma interferon in active chronic multiple sclerosis lesions. Ann N Y Acad Sci 540:309–311Google Scholar
- 42.Trotter JL, Clifford DB, Anderson CB, Van Der Veen RC, Hicks BC, Banks G (1988) Elevated serum interleukin-2 levels in chronic progressive multiple sclerosis (letter). N Engl J Med 318:1206Google Scholar
- 44.Tsukada N, Miyagi M, Matsuda M, Yanagisawa N, Yone K (1991) Tumor necrosis factor and interleukin-1 in the CSF and sera of patients with multiple sclerosis. J Neurol Sci 102:230–234Google Scholar